Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its blockbuster PD-1 inhibitor, Keytruda, approaches patent expiration in 2028.

With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are ...

Vaccine hesitancy is widely recognized as one of the most significant public health problems of the 21 st Century. The World Health Organization (WHO) identifies vaccine hesitancy ...

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "M-M-R II Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...

In this week’s edition of InnovationRx, we look at the richest five healthcare billionaires, Lilly’s first big AI success, ...

According to Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, the pharmaceutical industry is becoming more interested in targeted radiation therapy as a novel, promising cancer ...

The FDA has approved a third respiratory syncytial virus vaccine for high-risk adults aged younger than 50 years — a ...

By Ahmed Aboulenein and Julie Steenhuysen WASHINGTON, March 10 (Reuters) - The U.S. FDA approved leucovorin, a decades-old ...

GSK said the Food and Drug Administration expanded the approved age indication of its RSV vaccine to adults between the ages of 18 and 49 with increased risk of lower respiratory tract disease.

March 13 (Reuters) - British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age ...

This will be Prasad’s second exit from the FDA during the current Trump administration. In July, he resigned amid his controversial handling of a gene therapy treatment for Duchenne muscular dystrophy ...

The prescription drug leucovorin is getting a label update, though it’s not what that the US Food and Drug Administration suggested might be coming during a White House briefing in September, when ...